Studies On Psilocybin

 

Psilocybin and other Psychedelic substances like LSD have actually the subject of academic research and study for almost 70 years, albeit with a 30 hiatus during the ill-fated “war on drugs”. Doctors and Therapists have long been interested in these substances ability to elicit meaningful and transformative experiences with long lasting positive effects, and there were several studies which went on during the 1950s and 60s. While this early research showed immense promise for the use of psychedelics as a treatment, unfortunately the study of these substrances was abruptly halted for about 30 years, until 1997, when the first post-drug-war Psilocybin study was conducted by a team of researchers at the University of Zurich.

A team of researchers led by Dr. Franz Vollenweider explored whether brain function under the influence of psilocybin was consistent with the brain function of chronic schizophrenia patients, finding that these brain states were significantly contrasted. They also found that psilocybin increased cerebral glucose metabolism (in layman’s terms brain activity) in many areas, and had dampening effects on the ego-influenced Default Mode Network. 

Studies and early-phase clinical trials already concluded at John Hopkins University, The Multidisciplinary Association for Psychedelic Studies (MAPS), The Beckley Foundation, Yale, Stanford, Berkeley, New York University, and more have shown Psychedelics to be both safe and efficient in treating a host of psychological conditions. Some of these conditions include depression, addiction, anxiety, OCD, PTSD, and eating disorders.

In the decades since the turn of the century public attitude has also positively shifted towards the unfettered and open-minded research of psilocybin. Now, in 2020, governing bodies are beginning to follow suit. The FDA (Federal Drug Administration) has designated psilocybin a breakthrough therapy for Major Depressive Disorder (MDD), and Health Canada has granted several licenses to private and public companies in order to study psychedelics, most prominently psilocybin. 

Over a dozen accredited institutions, a few of which include Harvard, StanfordYaleThe Usona InstituteThe Heffter InstituteJohns Hopkins Universityand the University of Toronto are in the process of clinical trials/studies to determine the potential of psilocybin as a therapeutic aid, and there is a mountain of anecdotal evidence that cannot be discounted.

A collage of various university and institutional logos, including Stanford, Johns Hopkins, UC Berkeley, Penn, University of Zurich, Imperial College London, Columbia, NYU, Yale, VA, University of Toronto, Harvard, King's College London, University of Bristol, Purdue, McMaster, University of Basel, Utrecht, U.S. Department of Veterans Affairs, and UC San Diego School of Medicine.
Psilocybin and other Psychedelic substances like LSD have actually the subject of academic research and study for almost 70 years, albeit with a 30 hiatus during the ill-fated “war on drugs”. Doctors and Therapists have long been interested in these substances ability to elicit meaningful and transformative experiences with long lasting positive effects, and there were several studies which went on during the 1950s and 60s. While this early research showed immense promise for the use of psychedelics as a treatment, unfortunately the study of these substrances was abruptly halted for about 30 years, until 1997, when the first post-drug-war Psilocybin study was conducted by a team of researchers at the University of Zurich.

A team of researchers led by Dr. Franz Vollenweider explored whether brain function under the influence of psilocybin was consistent with the brain function of chronic schizophrenia patients, finding that these brain states were significantly contrasted. They also found that psilocybin increased cerebral glucose metabolism (in layman’s terms brain activity) in many areas, and had dampening effects on the ego-influenced Default Mode Network. 

Studies and early-phase clinical trials already concluded at John Hopkins University, The Multidisciplinary Association for Psychedelic Studies (MAPS), The Beckley Foundation, Yale, Stanford, Berkeley, New York University, and more have shown Psychedelics to be both safe and efficient in treating a host of psychological conditions. Some of these conditions include depression, addiction, anxiety, OCD, PTSD, and eating disorders.

In the decades since the turn of the century public attitude has also positively shifted towards the unfettered and open-minded research of psilocybin. Now, in 2020, governing bodies are beginning to follow suit. The FDA (Federal Drug Administration) has designated psilocybin a breakthrough therapy for Major Depressive Disorder (MDD), and Health Canada has granted several licenses to private and public companies in order to study psychedelics, most prominently psilocybin. 

Over a dozen accredited institutions, a few of which include Harvard, StanfordYaleThe Usona InstituteThe Heffter InstituteJohns Hopkins Universityand the University of Toronto are in the process of clinical trials/studies to determine the potential of psilocybin as a therapeutic aid, and there is a mountain of anecdotal evidence that cannot be discounted.

Universitiespng-min.jpg

Some of the claims made regarding psilocybin and its capability to treat a variety of conditions on a long term basis, with low frequency of dosage, may seem exaggerated or outlandish. However they are backed by a body of credible research that is constantly expanding.

We have curated a collection of the most relevant studies specific to Psilocybin below.

Want to learn more about Psychedelics?